Therapeutic agent for nervous system disease

Patent metadata

Field	Value
Publication number	US-12029751-B2
Application number	US-202318143370-A
Country	US
Kind code	B2
Filing date	May 4, 2023
Priority date	Dec 21, 2017
Publication date	Jul 9, 2024
Grant date	Jul 9, 2024

Abstract

An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin B 12 as an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

First claim

The invention claimed is:

1. A method of treating a cerebral infarction, the method comprising:
administering, to a patient with the cerebral infarction, an agent comprising an effective amount of methylcobalamin, by continuous intravenous drip infusion administration for a period of time.

2. The method according to claim 1 , wherein the administration is started immediately after onset of the cerebral infarction or within 12 hours of the onset.

3. The method according to claim 1 , wherein the effective amount of methlycobalamin is an amount effective for promoting M2 macrophage/microglia induction and inhibiting M1 macrophage/microglia induction.

4. The method according to claim 1 , wherein the effective amount of methlycobalamin is an amount effective for reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia.

Assignees

• Univ Osaka
• Nippon Zoki Pharmaceutical Co

Inventors

• Tanaka Hiroyuki
• Yoshikawa Hideki
• Mochizuki Hideki
• Murase Tsuyoshi
• Sasaki Tsutomu
• Baba Kousuke
• Iwahashi Toru
• Naiki Mitsuru

Classifications

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title